Assessing the Burden of Respiratory Syncytial Virus (RSV)

NCT07015255 | Not Yet Recruiting

• 1 other identifier: DOH/ADHRTC/2025/361
• Study Type: observational
• Target: 1,500
• Locations: 1 country
• Sites: 1

Brief Summary

This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:

• How often does RSV occur
• Who is most at risk
• The long-term and financial effects of RSV

Conditions

Respiratory Syncytial Virus (RSV) Infection; Acute Lower Respiratory Tract Infections; Bronchiolitis; Pneumonia; Chronic Respiratory Conditions

Keywords

Respiratory Syncytial Virus; RSV; RSV Infection; RSV in Infants; RSV in Adults; RSV Hospitalization; RSV Epidemiology; RSV Burden; RSV Risk Factors; Retrospective Study; Observational Study; ICU Admissions; RSV Mortality; RSV Cost Analysis; RSV Complications; Asthma and RSV; Bronchiolitis; Pneumonia; Recurrent Wheezing; RSV Surveillance; RSV-Related Comorbidities

Outcome Measures

Primary Outcomes (2)

• Burden of RSV Infection Across All Age Groups

  Measurement of the incidence of confirmed RSV infections in patients of all ages using SEHA hospital data from January 2018 to December 2024.

  January 2018 - December 2024

• Burden of RSV Infection Across All Age Groups

  Measurement of the prevalence of confirmed RSV infections in patients of all ages using SEHA hospital data from January 2018 to December 2024.

  January 2018 - December 2024

Secondary Outcomes (7)

• Identification of Risk Factors for Severe RSV Infection

  January 2018 - December 2024

• Proportion of Hospital Admissions Due to RSV

  January 2018 - December 2024

• ICU Admission Rates for RSV-Infected Patients

  January 2018 - December 2024

• Financial Burden of RSV Infection

  January 2018 - December 2024

• Incidence of Recurrent Wheezing and Asthma Diagnosis Following RSV Infection

  Up to 12 months post-infection

Study Arms (1)

Infants, adults, elderly, and high-risk patients with confirmed RSV infection (2018-2024).

This retrospective study includes patients of all ages with confirmed Respiratory Syncytial Virus (RSV) infection from January 2018 to December 2024, categorized into four cohorts: (1) Infants and young children, including those with risk factors such as prematurity, low birth weight, and chronic lung or heart disease; (2) Adults aged 18-64 years with or without comorbidities; (3) Elderly adults aged 65 and older, with focus on severe outcomes and mortality; and (4) High-risk individuals across all age groups with underlying conditions such as asthma, COPD, diabetes, immunosuppression, Down syndrome, or cystic fibrosis. No interventions are administered; the study analyzes existing data to assess RSV burden, ICU admissions, long-term health impacts, and associated healthcare costs.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study includes all patients of any age who have a laboratory-confirmed diagnosis of Respiratory Syncytial Virus (RSV) infection recorded in the SEHA electronic medical records between January 2018 and December 2024. The population spans from newborn infants to elderly adults, including those with underlying medical conditions such as chronic lung disease, heart disease, immunosuppression, and other comorbidities that may influence RSV severity. Both hospitalized patients and those diagnosed in outpatient settings within SEHA healthcare facilities are included. The study aims to represent the full spectrum of RSV disease burden, clinical outcomes, risk factors, long-term health impacts, and healthcare costs across diverse demographic groups in the UAE.

You may qualify if:

• Patients of all ages with a confirmed diagnosis of RSV infection
• Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024
• Patients with documented data in the SEHA electronic medical record (EMR) system

You may not qualify if:

• Patients with suspected RSV infection that is not laboratory-confirmed
• Patients without sufficient data in the SEHA EMR system

Sponsors & Collaborators

• Abu Dhabi Health Services Company: lead

Study Sites (1)

Sheikh Khalifa Medical City (Abu Dhabi Health Research Centre), SEHA

Abu Dhabi, United Arab Emirates

Location

Related Publications (8)

• Felton DA. A time of 'firsts'. J Prosthodont. 2004 Mar;13(1):1-2. doi: 10.1111/j.1532-849X.2004.04011.x. No abstract available.

  PMID: 15032890 BACKGROUND

• Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012 May;54(10):1427-36. doi: 10.1093/cid/cis211. Epub 2012 Apr 10.

  PMID: 22495079 BACKGROUND

• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5;360(6):588-98. doi: 10.1056/NEJMoa0804877.

  PMID: 19196675 BACKGROUND

• Wassmer SC, Lepolard C, Traore B, Pouvelle B, Gysin J, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis. 2004 Jan 15;189(2):180-9. doi: 10.1086/380761. Epub 2004 Jan 9.

  PMID: 14722881 BACKGROUND

• Callen A, Diener-West M, Zeitlin PL, Rubenstein RC. A simplified cyclic adenosine monophosphate-mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function. J Pediatr. 2000 Dec;137(6):849-55. doi: 10.1067/mpd.2000.109198.

  PMID: 11113843 BACKGROUND

• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951.

  PMID: 15858184 BACKGROUND

• Joury J, Al Kaabi N, Al Dallal S, Mahboub B, Zayed M, Abdelaziz M, Onwumeh-Okwundu J, Fletcher MA, Kumaresan S, Ramachandrachar BC, Farghaly M. Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023). J Health Econ Outcomes Res. 2024 Nov 5;11(2):133-144. doi: 10.36469/001c.123889. eCollection 2024.

  PMID: 39575134 BACKGROUND

• Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.

  PMID: 20399493 BACKGROUND

Related Links

• World Health Organization (WHO) - RSV Fact Sheet
• Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.
• Respiratory syncytial virus infection in elderly and high-risk adults.
• Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid.
• Risk factors for severe respiratory syncytial virus infection in elderly persons.
• The burden of respiratory syncytial virus infection in young children.
• Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.
• Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.

MeSH Terms

Conditions

Infections; Bronchiolitis; Pneumonia; Respiratory Syncytial Virus Infections; Asthma; Respiratory Sounds

Condition Hierarchy (Ancestors)

Bronchitis; Respiratory Tract Infections; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Pneumovirus Infections; Paramyxoviridae Infections; Mononegavirales Infections; RNA Virus Infections; Virus Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Salah Eldin Hussein, MD

  Abu Dhabi Health Services Company-SEHA

  STUDY DIRECTOR

• Nawal Alkaabi, MD

  Abu Dhabi Health Services Company-SEHA

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lina Khairy, MD

CONTACT

+971589111897; o-lkhayri@seha.ae

Alina Naeem, MBBS, MS

CONTACT

+971566089799; alina.naeem@purehealth.ae

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 16, 2025
• First Posted: June 11, 2025
• Study Start: June 1, 2025
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: June 19, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

AE (1)